This is the authors' abstract. We don't add key points for this paper.
This study investigates the potential of alkaloids – nitidine, harmine, harmaline, berberine, and magnoflurine – as inhibitors of HIV –CD4 binding, focusing on their molecular interactions, binding affinities, and pharmacokinetic properties. Molecular docking results revealed that all alkaloids exhibited high-affinity binding to the CD4 receptor and showed significant interactions with the HIV spike protein ( HIV -SP). Interaction analysis showed that nitidine and harmaline formed hydrogen bonds and hydrophobic interactions, while harmine and magnoflurine relied on van der Waals forces and π-stacking. Pharmacokinetic evaluations, based on Lipinski’s Rule of Five, showed that nitidine and magnoflurine exhibited favorable oral bioavailability, moderate lipophilicity, and blood–brain barrier permeability, with nitidine having a bioavailability score of 0.55, and showing promising candidate for the development of anti- HIV therapeutics, supported by their binding solid affinities, stability in MD simulations, and favorable pharmacokinetic profiles. MD simulations confirmed the stability of the CD4– HIV -SP complex, with magnesium fluoride showing the highest strength and minimal structural deviation, while nitidine and berberine exhibited binding solid stability. MM-GBSA calculations confirmed magnesium fluoride as the most potent inhibitor with the highest binding free energy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zafar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: